Side Effects of Immunosuppressive Regimens After Renal Transplantation and Multiple-Sample Assessment of Quality of Life
American Journal of Clinical and Experimental Medicine
Volume 5, Issue 3, May 2017, Pages: 69-74
Received: Apr. 11, 2017; Published: Apr. 12, 2017
Views 2313      Downloads 124
Authors
Siwen Wei, College of Pharmacy, Inner Mongolia Medical University, Hohhot, P. R. China
Na Yi, College of Pharmacy, Inner Mongolia Medical University, Hohhot, P. R. China
Lidao Bao, College of Pharmacy, Inner Mongolia Medical University, Hohhot, P. R. China
Article Tools
Follow on us
Abstract
Influences of the side effects and interferences of immunosuppressants on the quality of life (QOL) of renal transplant recipients have been discussed. 72 renal transplant recipients were surveyed utilizing 25-item health status questionnaires, and modified transplant symptom occurrence and symptom distress scales. The results showed that the frequencies and symptom interferences of side effect after receiving immunosuppressants were below medium level. Physical and mental health related QOL was most significantly affected by symptom occurrence and symptom distress, respectively. Besides, postoperative comorbidity, work status, age and household income have also been demonstrated to be able to predict the postoperative QOL. Side effects all occurred to various extents after receiving immunosuppressants to the renal transplant recipients, the occurrence and interference of the symptoms were not apparent, which would affect the postoperative QOL.
Keywords
Renal Transplantation, Drug Side Effect, Rational Use, High Quality Nursing
To cite this article
Siwen Wei, Na Yi, Lidao Bao, Side Effects of Immunosuppressive Regimens After Renal Transplantation and Multiple-Sample Assessment of Quality of Life, American Journal of Clinical and Experimental Medicine. Vol. 5, No. 3, 2017, pp. 69-74. doi: 10.11648/j.ajcem.20170503.13
References
[1]
Guo FF, Shao ZQ, Yang WY, Wang GJ, Tan SF, He XF, et al. Clinical analysis of living related renal transplantation with donors older than 50 years in China. Transplant Proc 2010,42:2471-2476.
[2]
Li QS, Huo WQ, Nie ZL, Wang HF, Liang PH, Jin FS. Acute femoral neuropathy following renal transplantation: a retrospective, multicenter study in China. Transplant Proc 2010,42:1699-1703.
[3]
Li L, Sun Q. Renal transplantation in China: ten years of experience at Nanjing Jinling Hospital. Clin Transpl 2006:71-77.
[4]
Winsett RP, Hathaway DK. Predictors of QoL in renal transplant recipients: bridging the gap between research and clinical practice. Posttransplant Quality of Life Intervention Study Group. ANNA J 1999,26:235-240.
[5]
Mingardi G. Quality of life and end stage renal disease therapeutic programs. DIA-QOL Group. Dialysis quality of life. Int J Artif Organs 1998, 21:741-747.
[6]
Padrao MB, Sens YA. Quality of life of living kidney donors in Brazil: an evaluation by the short form-36 and the WHOQOL-bref questionnaires. Clin Transplant 2009,23:621-627.
[7]
Nowicki M, Zwiech R, Dryja P, Sobanski W. Autonomic neuropathy in hemodialysis patients: questionnaires versus clinical tests. Clin Exp Nephrol 2009,13:152-155.
[8]
Ricci Z, Picardo S, Ronco C. Results from international questionnaires. Contrib Nephrol 2007, 156:297-303.
[9]
Dobbels F, Moons P, Abraham I, Larsen CP, Dupont L, De Geest S. Measuring symptom experience of side-effects of immunosuppressive drugs: the Modified Transplant Symptom Occurrence and Distress Scale. Transpl Int 2008, 21:764-773.
[10]
Cleemput I, Kesteloot K, Moons P, Vanrenterghem Y, Van Hooff JP, Squifflet JP, et al. The construct and concurrent validity of the EQ-5D in a renal transplant population. Value Health 2004, 7:499-509.
[11]
Dobbels F, Decorte A, Roskams A, Van Damme-Lombaerts R. Health-related quality of life, treatment adherence, symptom experience and depression in adolescent renal transplant patients. Pediatr Transplant 2010, 14:216-223.
[12]
Moons P, De Geest S, Abraham I, Cleemput JV, Van Vanhaecke J. Symptom experience associated with maintenance immunosuppression after heart transplantation: patients' appraisal of side effects. Heart Lung 1998, 27:315-325.
[13]
Sun YJ, Li AP, Pan ZQ, Luo F, Zou LH. [Systematic review of penetrating keratoplasty rejection treated by immunosuppressants]. Zhonghua Yan Ke Za Zhi 2010, 46:1122-1127.
[14]
Lee EK, Cham TM, Tseng PL. A retrospective study on the utilization of and expenditure for immunosuppressants for organ transplant recipients in Taiwan--updated to 2006. Transplant Proc 2010,42:961-965.
[15]
Quteineh L, Verstuyft C. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. Curr Opin Organ Transplant 2010, 15:601-607.
[16]
Chang JW, Tsai HL, Yang LY. Successful treatment of refractory septic arthritis caused by salmonella and staphylococcus aureus with preservation of graft function in a long-term renal transplant recipient by total withdrawal of immunosuppressants. Clin Nephrol 2010,73:72-75.
[17]
Greco M, Vitagliano T, Fiorillo MA, Greto Ciriaco A. A New Technique of Upper Eyelid Blepharoplasty Using the Orbicularis Muscle Flap. Aesthetic Plast Surg 2011.
[18]
Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007, 214:289-295.
[19]
Schonder KS, Mazariegos GV, Weber RJ. Adverse effects of immunosuppression in pediatric solid organ transplantation. Paediatr Drugs 2010, 12:35-49.
[20]
Zhang Y, Wang Y, Zhang P, Zhang XD, Yang Y. Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia. Transplant Proc 2009, 41:3747-3751.
[21]
Leon-Salas B, Olazaran J, Muniz R, Gonzalez-Salvador MT, Martinez-Martin P. Caregivers' estimation of patients' quality of life (QoL) in Alzheimer's disease (AD): an approach using the ADRQL. Arch Gerontol Geriatr 2011, 53:13-18.
[22]
Okushi T, Yoshikawa M, Otori N, Matsuwaki Y, Asaka D, Nakayama T, et al. Evaluation of symptoms and QOL with calcium alginate versus chitin-coated gauze for middle meatus packing after endoscopic sinus surgery. Auris Nasus Larynx 2012, 39:31-37.
[23]
Brocker KA, Alt CD, Corteville C, Hallscheidt P, Lenz F, Sohn C. Short-range clinical, dynamic magnetic resonance imaging and P-QOL questionnaire results after mesh repair in female pelvic organ prolapse. Eur J Obstet Gynecol Reprod Biol 2011, 157:107-112.
[24]
Claerhout F, Moons P, Ghesquiere S, Verguts J, De Ridder D, Deprest J. Validity, reliability and responsiveness of a Dutch version of the prolapse quality-of-life (P-QoL) questionnaire. Int Urogynecol J 2010, 21:569-578.
[25]
Mor V. QOL measurement scales for cancer patients: differentiating effects of age from effects of illness. Oncology (Williston Park) 1992, 6:146-152.
[26]
Boyer L, Simeoni MC, Loundou A, D'Amato T, Reine G, Lancon C, et al. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res 2010, 121:241-250.
[27]
Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R. Low-dose, short-term ciclosporin (Neoral(R)) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol 2011, 38:465-472.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186